關鍵數據
23.840今開
24.990最高
636.27K成交量
21.70本益比TTM
12.39本益比動
--股利TTM
0.79%換手率
24.000昨收
22.501最低
15.37M成交額
80.58本益比靜
1.36市淨率
0.00%股息率 TTM
6.40%ROA
60.91052週最高
0.16量比
24.14M淨利潤
80.39M總股本
1.1150每股盈餘TTM
1.98Beta
6.93%ROE
21.91052週最低
32.83%振幅
71.49%毛利率
1.94B總市值
-9.91回報/風險
5.09%風險率

即將為您帶來更多新聞,敬請期待。 。 。
Veracyte Inc評分
-0.32與上次評分對比預測8.83
財務診斷8.11
技術分析6.13
公司估值6.85
機構認同度10.00
風險評估2.25
分析師評級
買入評級
58.545目標均價
+17.07%漲幅空間
Veracyte Inc 最新財報電話會記錄
Veracyte (VCYT) 2026年第三季法說會:Decipher 展望重設,2027年成長放緩
Veracyte 2026 年第三季營收成長 15% 至 1.518 億美元,但該公司重新調整了 Decipher 的成長預期,並預測 2027 年營收將呈現中個位數成長。
財務指標
貨幣: USD

由於公司未披露,未能獲取相關數據
貨幣: USD

由於公司未披露,未能獲取相關數據
Veracyte Inc 簡介
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
行業生物技術與醫療研究
公司代碼VCYT
員工數量824
國家United States of America
持股情況
| 持股股東 | 佔比 |
|---|
| BlackRock Institutional Trust Company, N.A. | 14.43% |
|---|
| Artisan Partners Limited Partnership | 6.89% |
|---|
| State Street Investment Management (US) | 6.32% |
|---|
| Fidelity Management & Research Company LLC | 6.12% |
|---|
| 股東類型 | 佔比 |
|---|
| Investment Advisor | 64.19% |
|---|
| Investment Advisor/Hedge Fund | 34.77% |
|---|
| Hedge Fund | 5.42% |
|---|
| Research Firm | 3.29% |
|---|
常見問題
Veracyte Inc(VCYT)的當前股價是多少?
Veracyte Inc(VCYT)的當前股價是 24.16。
Veracyte Inc股票的52週最高點是多少?
Veracyte Inc股票的52週最高點是60.91。
Veracyte Inc股票的52週最低點是多少?
Veracyte Inc股票的52週最低點是21.91。
現在Veracyte Inc(VCYT)的股票是買入、持有還是賣出?
根據分析師評級,Veracyte Inc(VCYT)的總體評級為買入,目標價格為58.55。
Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是多少
Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是1.11。